Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). Adamas Pharmaceuticals is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Read the full article: Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2021/10/11/2311671/19871/en/Supernus-Pharmaceuticals-to-Acquire-Adamas-Pharmaceuticals-Strengthening-its-CNS-Product-Portfolio.html